1. Xenoextracellular matrix-rosiglitazone complex-mediated immune evasion promotes xenogenic bioengineered root regeneration by altering M1/M2 macrophage polarization
   Tingting Lan et al, 2021, Biomaterials CrossRef
2. The Brown Algae Ishige sinicola Extract Ameliorates Ovariectomy-Induced Bone Loss in Rats and Suppresses Osteoclastogenesis through Downregulation of NFATc1/c-Fos
   Mihyang Kim et al, 2022, Nutrients CrossRef
3. A novel drug combination of Tofacitinib and Iguratimod alleviates rheumatoid arthritis and secondary osteoporosis
   Jie Chen et al, 2023, International Immunopharmacology CrossRef
4. Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
   Sisi Xie et al, 2020, Frontiers in Pharmacology CrossRef
5. Influence of Iguratimod on Bone Metabolism in Patients with Rheumatoid Arthritis: A Meta-analysis
   Li Deng et al, 2022, International Journal of Clinical Practice CrossRef
6. The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab
   Kosuke Ebina et al, 2019, Modern Rheumatology CrossRef
7. Anti-fibrotic effect of iguratimod on pulmonary fibrosis by inhibiting the fibroblast–to-myofibroblast transition
   Haobo Lin et al, 2020, Advances in Medical Sciences CrossRef
8. Baohuoside I Inhibits Osteoclastogenesis and Protects Against Ovariectomy-Induced Bone Loss
   Min Ma et al, 2022, Frontiers in Pharmacology CrossRef
9. Iguratimod Restrains Circulating Follicular Helper T Cell Function by Inhibiting Glucose Metabolism via Hif1α-HK2 Axis in Rheumatoid Arthritis
   Ziran Bai et al, 2022, Frontiers in Immunology CrossRef
10. Effectiveness and Safety of Iguratimod in Treating Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis
    Jincheng Pu et al, 2021, Frontiers in Pharmacology CrossRef
11. Cardiovascular Involvement in Sjögren’s Syndrome
    Fabiola Atzeni et al, 2022, Frontiers in Immunology CrossRef
12. Role of PPARs in Progression of Anxiety: Literature Analysis and Signaling Pathways Reconstruction
    Olga I. Rudko et al, 2020, PPAR Research CrossRef
13. Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways
    Chang-hong Li et al, 2021, International Immunopharmacology CrossRef
14. Efficacy and safety of Iguratimod in the treatment of Ankylosing Spondylitis: A systematic review and meta-analysis of randomized controlled trials
    Zhiyong Long et al, 2023, Frontiers in Immunology CrossRef
15. Efficacy and safety of iguratimod combined with methotrexate vs. methotrexate alone in rheumatoid arthritis
    L.-J. Chen et al, 2021, Zeitschrift für Rheumatologie CrossRef
16. Effects of iguratimod on glucocorticoid-induced disorder of bone metabolism in vitro
    Akira Miyama et al, 2021, Journal of Bone and Mineral Metabolism CrossRef
17. The PPAR-γ antagonist T007 inhibits RANKL-induced osteoclastogenesis and counteracts OVX-induced bone loss in mice
    Xiang Li et al, 2019, Cell Communication and Signaling CrossRef
18. Cinnamic acid decreases periodontal inflammation and alveolar bone loss in experimental periodontitis
    Ozkan Karatas et al, 2020, Journal of Periodontal Research CrossRef
19. Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology
    Jie Li et al, 2019, Bone Research CrossRef
20. Molecular mechanisms and clinical application of Iguratimod: A review
    Huihui Jiang et al, 2020, Biomedicine & Pharmacotherapy CrossRef
21. Iguratimod suppresses sclerostin and receptor activator of NF-κB ligand production via the extracellular signal–regulated kinase/early growth response protein 1/tumor necrosis factor alpha pathway in osteocytes and ameliorates disuse osteoporosis in mice
    Taihei Miura et al, 2024, Bone CrossRef